235 related articles for article (PubMed ID: 11886478)
1. Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy.
Hiatt WR
J Intern Med; 2002 Mar; 251(3):193-206. PubMed ID: 11886478
[TBL] [Abstract][Full Text] [Related]
2. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
CAPRIE Steering Committee
Lancet; 1996 Nov; 348(9038):1329-39. PubMed ID: 8918275
[TBL] [Abstract][Full Text] [Related]
3. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
Hacke W
Cerebrovasc Dis; 2002; 13 Suppl 1():22-6. PubMed ID: 11803184
[TBL] [Abstract][Full Text] [Related]
4. Rationale for the use of platelet aggregation inhibitors in PAD patients.
Agnelli G
Vasc Med; 2001; 6(3 Suppl):13-5. PubMed ID: 11789961
[TBL] [Abstract][Full Text] [Related]
5. Clopidogrel: a review of its use in the prevention of atherothrombosis.
Jarvis B; Simpson K
Drugs; 2000 Aug; 60(2):347-77. PubMed ID: 10983738
[TBL] [Abstract][Full Text] [Related]
6. Evidence with antiplatelet therapy and ADP-receptor antagonists.
Easton JD
Cerebrovasc Dis; 2003; 16 Suppl 1():20-6. PubMed ID: 12698015
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet therapy in peripheral arterial disease.
Aronow WS
Curr Drug Targets Cardiovasc Haematol Disord; 2004 Sep; 4(3):265-7. PubMed ID: 15379619
[TBL] [Abstract][Full Text] [Related]
8. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease.
Montalescot G
Clin Cardiol; 2000 Nov; 23 Suppl 6(Suppl 6):VI-18-22. PubMed ID: 11129682
[TBL] [Abstract][Full Text] [Related]
9. Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Mohler ER
Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S1-6. PubMed ID: 19213065
[TBL] [Abstract][Full Text] [Related]
10. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
Diener HC; Bogousslavsky J; Brass LM; Cimminiello C; Csiba L; Kaste M; Leys D; Matias-Guiu J; Rupprecht HJ
Cerebrovasc Dis; 2004; 17(2-3):253-61. PubMed ID: 14981346
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease.
Aronow WS
Drugs Aging; 1999 Aug; 15(2):91-101. PubMed ID: 10495069
[TBL] [Abstract][Full Text] [Related]
12. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Tran H; Anand SS
JAMA; 2004 Oct; 292(15):1867-74. PubMed ID: 15494585
[TBL] [Abstract][Full Text] [Related]
13. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
Hankey GJ; Sudlow CL; Dunbabin DW
Cochrane Database Syst Rev; 2000; (2):CD001246. PubMed ID: 10796426
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection.
Zusman RM; Chesebro JH; Comerota A; Hartmann JR; Massin EK; Raps E; Wolf PA
Clin Cardiol; 1999 Sep; 22(9):559-73. PubMed ID: 10486695
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet therapy in populations at high risk of atherothrombosis.
Faxon DP; Nesto RW
J Natl Med Assoc; 2006 May; 98(5):711-21. PubMed ID: 16749646
[TBL] [Abstract][Full Text] [Related]
16. [The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients].
Drouet L; Bal dit Sollier C; Henry P
Drugs; 2010 Nov; 70 Suppl 1():9-14. PubMed ID: 20977287
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
Scheen AJ
Rev Med Liege; 2001 Mar; 56(3):186-9. PubMed ID: 11338792
[TBL] [Abstract][Full Text] [Related]
18. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Logman JF; Heeg BM; Herlitz J; van Hout BA
Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
[TBL] [Abstract][Full Text] [Related]
19. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
Sudlow CL; Mason G; Maurice JB; Wedderburn CJ; Hankey GJ
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD001246. PubMed ID: 19821273
[TBL] [Abstract][Full Text] [Related]
20. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL; Topol EJ;
Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
